HC Wainwright restated their buy rating on shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) in a report issued on Tuesday morning. They currently have a $3.50 price objective on the biotechnology company’s stock.

A number of other analysts have also recently weighed in on the stock. Maxim Group reaffirmed a buy rating and issued a $2.00 price objective on shares of Pluristem Therapeutics in a report on Tuesday, September 5th. ValuEngine cut shares of Pluristem Therapeutics from a sell rating to a strong sell rating in a report on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of $3.19.

Pluristem Therapeutics (PSTI) opened at 1.46 on Tuesday. The stock’s 50 day moving average is $1.20 and its 200-day moving average is $1.28. The firm’s market capitalization is $142.31 million. Pluristem Therapeutics has a 52 week low of $1.04 and a 52 week high of $1.66.

TRADEMARK VIOLATION WARNING: “Pluristem Therapeutics, Inc. (PSTI) Given “Buy” Rating at HC Wainwright” was published by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.dailypolitical.com/2017/09/20/pluristem-therapeutics-inc-psti-given-buy-rating-at-hc-wainwright-2.html.

An institutional investor recently raised its position in Pluristem Therapeutics stock. Renaissance Technologies LLC raised its stake in shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) by 9.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,553,800 shares of the biotechnology company’s stock after buying an additional 129,000 shares during the period. Renaissance Technologies LLC owned approximately 1.62% of Pluristem Therapeutics worth $1,911,000 as of its most recent SEC filing. 4.47% of the stock is owned by institutional investors.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.

Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.